Emergent BioSolutions Announces Early
Termination of HSR Waiting Period for Its
Acquisition of Trubion Pharmaceuticals
September 08, 2010 04:03 PM Eastern Daylight Time
ROCKVILLE, Md.--(EON: Enhanced Online News)--Emergent BioSolutions Inc. (NYSE:EBS) announced today
that the U.S. Department of Justice and Federal Trade Commission granted early termination of the waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR Act"), as amended, with respect to the
planned acquisition of Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) by Emergent BioSolutions announced on
August 12, 2010. Accordingly, the requirement under the merger agreement for the expiration or termination of any
waiting period under the HSR Act has been satisfied. The closing of the transaction still remains subject to other
conditions in the definitive merger agreement, including approval by Trubion’s stockholders.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and
commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat
disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by
the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent’s product pipeline targets
infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
About Trubion Pharmaceuticals, Inc.
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to
treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-
class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes
may offer improved patient experiences. Trubion's current product candida